CellVoyant Secures £7.6M Seed Funding to Advance AI-Driven Stem Cell Therapies for Chronic Diseases.
CellVoyant is at the forefront of biotechnology, leveraging artificial intelligence to revolutionize the development of stem cell therapies.
Company Name: CellVoyant
Location: Bristol, UK
Sector: AI-First Biotechnology for Stem Cell Therapies
Funding Details: Raised £7.6M in Seed funding, led by Octopus Ventures, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital.
Purpose of Investment: To scale the business, including doubling the team size over the next two years, expanding laboratory and experimental infrastructure, and advancing AI capabilities.
Leadership: Professor Rafael Carazo Salas, Founder and CEO
Product: CellVoyant is pioneering in the field of stem cell-based therapies for chronic diseases using AI-first live cell imaging technology. This innovative approach predicts and optimizes stem cell differentiation, enabling the scalable manufacturing of any cell and tissue type in the body.
About Company: CellVoyant is at the forefront of biotechnology, leveraging artificial intelligence to revolutionize the development of stem cell therapies. With a focus on chronic diseases, CellVoyant's groundbreaking technology aims to transform the therapeutic landscape by enabling controllable and scalable production of cells and tissues. The company's recent seed funding underscores its potential to lead advancements in regenerative medicine, highlighting the crucial role of AI in optimizing stem cell differentiation processes for therapeutic applications.